Crinetics Pharmaceuticals (CRNX) Revenue & Revenue Breakdown
Crinetics Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$4.01M
Crinetics Pharmaceuticals Revenue by Period
Crinetics Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $4.01M | -15.28% |
| 2022-12-31 | $4.74M | 339.42% |
| 2021-12-31 | $1.08M | 1418.31% |
| 2020-12-31 | $71.00K | -94.05% |
| 2019-12-31 | $1.19M | -50.86% |
| 2018-12-31 | $2.43M | 18.73% |
| 2017-12-31 | $2.04M | 247.20% |
| 2016-12-31 | $589.00K | - |
Crinetics Pharmaceuticals generated $4.01M in revenue during NA 2023, up -15.28% compared to the previous quarter, and up 165.28% compared to the same period a year ago.
Crinetics Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-09-30 | - | -100.00% |
| 2024-06-30 | $399.00K | -37.66% |
| 2024-03-31 | $640.00K | 100.00% |
| 2023-12-31 | - | -100.00% |
| 2023-09-30 | $346.00K | -64.98% |
| 2023-06-30 | $988.00K | -63.12% |
| 2023-03-31 | $2.68M | 277.86% |
| 2022-12-31 | $709.00K | 54.80% |
| 2022-09-30 | $458.00K | 4.33% |
| 2022-06-30 | $439.00K | -85.98% |
| 2022-03-31 | $3.13M | 190.45% |
| 2021-12-31 | $1.08M | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | -100.00% |
| 2020-03-31 | $71.00K | -77.88% |
| 2019-12-31 | $321.00K | -36.44% |
| 2019-09-30 | $505.00K | 100.00% |
| 2019-06-30 | - | -100.00% |
| 2019-03-31 | $367.00K | -53.01% |
| 2018-12-31 | $781.00K | 42.52% |
| 2018-09-30 | $548.00K | -16.59% |
| 2018-06-30 | $657.00K | 48.64% |
| 2018-03-31 | $442.00K | -16.29% |
| 2017-12-31 | $528.00K | -17.50% |
| 2017-09-30 | $640.00K | -23.08% |
| 2017-06-30 | $832.00K | 1748.89% |
| 2017-03-31 | $45.00K | - |
Crinetics Pharmaceuticals generated - in revenue during Q3 2024, up -100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Crinetics Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| ALEC | Alector | $97.06M | $15.08M |
| RGNX | REGENXBIO | $90.24M | $24.20M |
| MRUS | Merus | $43.95M | $11.77M |
| CYTK | Cytokinetics | $7.53M | $463.00K |
| KZR | Kezar Life Sciences | $7.00M | - |
| KRON | Kronos Bio | $6.29M | $2.37M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | - |
| INBX | Inhibrx Biosciences | $1.80M | - |
| VRDN | Viridian Therapeutics | $314.00K | $86.00K |
| LYEL | Lyell Immunopharma | $130.00K | $34.00K |
| GPCR | Structure Therapeutics | - | - |
| BDTX | Black Diamond Therapeutics | - | - |
| PASG | Passage Bio | - | - |